Watertown, MA, United States of America

Melissa Myint

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Stemcell Technologies Canada Inc.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Melissa Myint

Introduction

Melissa Myint is an accomplished inventor based in Watertown, MA (US). She has made significant contributions to the field of medical technology, particularly in the treatment of diseases associated with human papillomavirus (HPV). Her innovative work has led to the development of a patent that addresses critical health issues.

Latest Patents

Melissa Myint holds a patent titled "Methods for Treating HPV-Associated Diseases." This patent represents her commitment to advancing medical treatments and improving patient outcomes. With 1 patent to her name, she continues to be a valuable asset in her field.

Career Highlights

Currently, Melissa is employed at Stemcell Technologies Canada Inc., where she collaborates with a team of experts to drive innovation in stem cell research and applications. Her work at this esteemed company highlights her dedication to scientific advancement and her role in developing cutting-edge solutions.

Collaborations

One of her notable coworkers is Leeann Talarico, who also contributes to the innovative environment at Stemcell Technologies Canada Inc. Together, they work towards achieving breakthroughs in their respective areas of expertise.

Conclusion

Melissa Myint's contributions to the field of medical technology through her patent and work at Stemcell Technologies Canada Inc. exemplify her dedication to innovation and improving healthcare solutions. Her efforts continue to inspire advancements in the treatment of HPV-associated diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…